Brief update of the new WHO classification for urothelial carcinoma

Compérat, Éva; Wasinger, Gabriel; Oszwald, André; Shariat, Shahrokh F.

doi:10.1097/mou.0000000000001020

Cited by 3 publications

(4 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A three-tiered grading system (grades 1, 2, and 3) for papillary urothelial tumors was first introduced in 1973 [24], and revisions occurred in 1998,1999,2004,2016, and 2022 to develop a modern system of grading [25][26][27][28]. Grading of the flat NMIBC follows a similar tiered grading system [1].…”

Section: Discussionmentioning

confidence: 99%

Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma

Hasan,

Mohammed,

Basiony

et al. 2023

Clinics and Practice

View full text Add to dashboard Cite

Introduction: The identification of bladder detrusor muscle invasion in urothelial cancer is essential for prognosis and management. We studied the clinical, histological, and immunohistochemical expression of p16, p53, and Ki-67 in urothelial detrusor muscle-invasive bladder cancer (MIBC) and urothelial non-detrusor muscle-invasive bladder cancer (NMIBC) in Egyptian patients. Methods: Sixty-two bladder urothelial cancer cases obtained through TURBT were included and divided into two groups: (MIBC, stage T2) and NMIBC (T1). Tissue blocks were recut and re-examined microscopically; then, the immunostaining of p16, p53, and Ki-67 was performed to compare both groups and evaluate the 13% cut-off for Ki-67, 20% for p53, and p16 intensity in various conditions aided by telepathology technology. Results and conclusion: Hematuria was the main clinical first presentation, with no significant difference between either group. The mean age was 61.6 years, with male predominance (52 males and 10 females). The absence of papillary histological pattern was associated with a higher stage, including detrusor muscle invasion (p = 0.000). The overall average percent of p53 immunostaining was 12.9%, revealing no significant difference between MIBC and NMIBC when a cut-off of 20% was implicated. The Ki-67 expression was correlated with higher grade and muscle invasion; however, no association was found with the other two markers’ expression. The negative immunostaining of p16 was associated with low grade and NMIBC in the case of the preservation of the papillary pattern. We recommend further studies on the cut-off of widely used markers and more immunohistochemical and genetic studies on the p16(INK4A), taking into consideration the histological pattern of conventional carcinomas.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma

Hasan,

Mohammed,

Basiony

et al. 2023

Clinics and Practice

View full text Add to dashboard Cite

show abstract

“…Bladder cancer is one of the most commonly diagnosed malignancies of the urinary tract and is characterized by low sensitivity to chemotherapy and a high recurrence rate ( Saginala et al, 2020 ; Compérat et al, 2022 ). Low-grade bladder cancer has a slow progression rate and hardly presents a threat to patients.…”

Section: Bladder Cancer and Non-coding Rnas (Ncrnas)mentioning

confidence: 99%

“…Urothelial carcinoma of the urinary bladder is the second most commonly diagnosed urogenital cancer ( Saginala et al, 2020 ; Compérat et al, 2022 ). On initial presentation, 70–75% of patients with bladder tumors are categorized as non-muscle invasive bladder cancer (NMIBC).…”

Section: Introductionmentioning

confidence: 99%

Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer

2023

View full text Add to dashboard Cite

Major fraction of the human genome is transcribed in to the RNA but is not translated in to any specific functional protein. These transcribed but not translated RNA molecules are called as non-coding RNA (ncRNA). There are thousands of different non-coding RNAs present inside the cells, each regulating different cellular pathway/pathways. Over the last few decades non-coding RNAs have been found to be involved in various diseases including cancer. Non-coding RNAs are reported to function both as tumor enhancer and/or tumor suppressor in almost each type of cancer. Urothelial carcinoma of the urinary bladder is the second most common urogenital malignancy in the world. Over the last few decades, non-coding RNAs were demonstrated to be linked with bladder cancer progression by modulating different signalling pathways and cellular processes such as autophagy, metastasis, drug resistance and tumor proliferation. Due to the heterogeneity of bladder cancer cells more in-depth molecular characterization is needed to identify new diagnostic and treatment options. This review emphasizes the current findings on non-coding RNAs and their relationship with various oncological processes such as autophagy, and their applicability to the pathophysiology of bladder cancer. This may offer an understanding of evolving non-coding RNA-targeted diagnostic tools and new therapeutic approaches for bladder cancer management in the future.

show abstract

“…The rising incidence of bladder cancer, shortage of medical experts, and lack of financial resources has become a challenge for global public health systems [1]. Bladder cancer is categorized mainly into non-muscle invasive (NMIBC) and muscle-invasive (MIBC) disease, considering detrusor muscle infiltration, which affects dramatically therapeutic planning [2]. NMIBC, accounting for 2/3 of patients presenting with bladder cancer, are highly recurrent tumors that are managed with a strict monitoring schedule with cystoscopy -for the assessment of the bladder -and CT-urography -for the assessment of the upper urothelial tract - [3], given the risk of progression to muscleinvasive stage up to 50% [4].…”

Section: Textmentioning

confidence: 99%

VI-RADS for the diagnosis and management of urinary bladder cancer

Panebianco

2023

Eur Radiol

View full text Add to dashboard Cite

Brief update of the new WHO classification for urothelial carcinoma

Cited by 3 publications

References 34 publications

Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma

Clinico-Pathological Features and Immunohistochemical Comparison of p16, p53, and Ki-67 Expression in Muscle-Invasive and Non-Muscle-Invasive Conventional Urothelial Bladder Carcinoma

Non-coding RNA and autophagy: Finding novel ways to improve the diagnostic management of bladder cancer

VI-RADS for the diagnosis and management of urinary bladder cancer

Contact Info

Product

Resources

About